id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1275-0013,FDA,FDA-2013-D-1275,"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T13:58:30Z,2022-19410,0,0,09000064852c87c2
FDA-2013-D-1275-0014,FDA,FDA-2013-D-1275,"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products Guidance for Industry; DRAFT GUIDANCE",Other,Guidance,2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,2022-12-08T04:59:59Z,2026-01-03T12:21:42Z,,1,0,09000064852b7e96
FDA-2013-D-1275-0002,FDA,FDA-2013-D-1275,Draft Guidance General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products Guidance for Industry,Other,Guidance,2014-12-09T05:00:00Z,2014,12,2014-12-09T05:00:00Z,,2024-11-12T05:31:32Z,,1,0,0900006481967deb
FDA-2013-D-1275-0001,FDA,FDA-2013-D-1275,"General Clinical Pharmacology Considerations for Pediatric 
Studies for Drugs and Biological Products; Draft Guidance for Industry; 
Availability",Notice,Notice of Availability,2014-12-09T05:00:00Z,2014,12,2014-12-09T05:00:00Z,2015-02-10T04:59:59Z,2015-02-25T03:05:16Z,2014-28716,0,0,0900006481967c22